SEC Form 4 · accession 0000911916-16-000658
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Mathers
Officer — Chief Executive Officer · Director
Period of report
Sep 14, 2016
Accepted (ET)
Sep 16, 2016 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 14, 2016 | S | 5,700 | $23.3004 | D | 244,714 | D | |
| Common StockF1,F3 | Sep 14, 2016 | S | 300 | $23.78 | D | 244,414 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016.
- F2Represents the sale of 5,700 shares in multiple transactions, ranging in price from $22.73 to $23.72 per share, resulting in a weighted average sale price of $23.3004. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Represents the sale of 300 shares in multiple transactions, ranging in price from $23.77 to $23.79 per share, resulting in a weighted average sale price of $23.78. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.